The start of today's session on Wall Street is marked by moderate optimism, with investors focusing on numerous quarterly earnings reports. Furthermore, at 4:00 p.m. CET, we will learn important ISM PMI data for the US services sector, which may influence future Fed decisions on interest rates and, consequently, investor sentiment.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appUS100 (D1 interval)
The Nasdaq-100 index, represented by the US100 contract, is trading nearly 0.05% higher today compared to yesterday's close. The index continues to maintain a dynamic upward trend, as illustrated by the exponential moving averages (50-, 100- and 200-day EMAs, respectively). What is more, Bollinger Bands show that US100 is currently within the statistical range of this instrument's movements for the last 14 sessions. The most important support point for the instrument remains the lower limit of the Bollinger Bands (2 negative standard deviations) and the 50-day EMA (blue curve).
Source: xStation 5
Company news:
Following Donald Trump's statements in which he accused Bank of America (BAC.US) and JP Morgan (JPM.US) of discriminating against each other, the shares of these banks are losing value slightly at the beginning of today's session.
Palantir Technologies (PLTR.US) shares are up 6% today after reporting results that exceeded expectations in terms of both revenue and net income. The company also provided an exceptionally strong forecast for the next quarter and the entire fiscal year in its report. Management emphasized that the growth is driven by increasing demand for AI solutions and a growing number of corporate customers.
Vertex Pharmaceuticals (VRTX.US) shares fell 15% despite quarterly results that exceeded analysts' expectations. The company reported revenue of $2.96 billion, up 12% year-over-year, and earnings per share of $4.52, exceeding forecasts. However, investors reacted negatively to the decision to halt further development of the painkiller VX-993, which failed to meet the primary endpoints of Phase 2 clinical trials. Despite successes in other areas, such as cystic fibrosis treatment and new product launches, the halting of the pain project raised concerns about the company's future prospects. Vertex confirmed its revenue forecast for 2025 at $11.85-12 billion, indicating an expected growth of approximately 8%.
Hims & Hers (HIMS.US) shares fell 13% after the release of its second quarter 2025 results. The company reported revenue of $544.8 million, up 73% year-over-year, but slightly below market expectations. Revenue from the GLP-1 segment, which includes weight loss drugs, fell quarter-on-quarter from $230 million to $190 million, negatively impacting investor sentiment. The decline was attributed to subscriber churn and regulatory challenges in the area.
Caterpillar (CAT.US) shares fell 4% after the release of its second quarter 2025 results. The company reported earnings per share (EPS) of $4.72, which was below analysts' expectations, although revenues were $16.6 billion and close to forecasts. Caterpillar forecasts the net impact of tariffs for the full fiscal year 2025 to be between $1.3 billion and $1.5 billion, which negatively affects margins and profitability. Despite the challenges posed by tariffs, the company maintains a solid cash position and generates high cash flow.
Archer-Daniels-Midland (ADM.US) shares fell 4% after reporting second-quarter 2025 results. Revenue was $21.17 billion, slightly below market expectations of $21.5 billion. Adjusted earnings per share (Adj. EPS) were 93 cents, exceeding the forecast of 80 cents. The company lowered its adjusted earnings forecast for the full fiscal year 2025 to $4.00 from its previous estimate of $4.00-$4.75, while pointing to the impact of tariffs of $1.3 billion to $1.5 billion. ADM is facing challenges in its agricultural services and oilseeds segments, which have impacted profitability. Despite these challenges, the company is maintaining a stable cost and investment strategy. Management emphasized the need to further optimize operations in the second half of the year. Investors reacted to this news with a decline in the stock price.
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
